{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:07:24Z","timestamp":1793398044837,"version":"4.5.0"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Despite expanded efforts to improve treatment access, inequities exist in the receipt of medications for opioid use disorder by race and ethnicity and insurance type.<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine inequities in access to medications for opioid use disorder (MOUD)\u2014specifically buprenorphine and naltrexone\u2014by race and ethnicity and insurance type after opioid-related health care events.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective cohort study used data from the Institute for Health Equity Research Multi-Payor Claims Database, which includes more than 130 million individuals across commercial, Medicaid, and Medicare Advantage insurance plans. The cohort consisted of patients aged 18 years or older with an opioid use disorder (OUD)\u2013related health care event (opioid-related overdose, infection, or treatment event) that occurred between January 1, 2017, and December 31, 2022. Statistical analysis was conducted from October 2023 to December 2024.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Race and ethnicity and insurance type, including commercial insurance, Medicaid, and Medicare Advantage, were the primary exposures.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was receipt of MOUD (buprenorphine or naltrexone) within 180 days of an OUD-related health care event. Logistic regression models were used to assess the associations of MOUD receipt with race and ethnicity and with insurance type, adjusting for demographic, clinical, time, and geographical covariates.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 176\u202f997 index events involving 164\u202f728 patients between 2017 and 2022, the mean (SD) patient age was 40.0 (13.1) years; 104\u202f005 (58.8%) involved men; 1083 events (0.6%) were among Asian patients, 23\u202f424 (13.2%) were among Black patients, 10\u202f302 (5.8%) were among Hispanic patients, 90\u202f124 (50.9%) were among White patients, and 4697 (2.7%) were among patients of other race and ethnicity; and 147\u202f257 (83.2%) were covered by Medicaid. Black (adjusted estimated probability, 17.1% [95% CI, 13.0%-21.1%]) and Hispanic (adjusted estimated probability, 16.2% [95% CI, 11.6%-20.8%]) patients were significantly less likely than White patients (adjusted estimated probability, 20.5% [95% CI, 16.4%-24.7%]) to receive buprenorphine (Black patients: adjusted odds ratio [AOR], 0.75 [95% CI, 0.63-0.90]; adjusted risk difference [ARD], \u22123.4 percentage points [pp] [95% CI, \u20136.5 to \u20130.4 pp]; Hispanic patients: AOR, 0.69 [95% CI, 0.51-0.92]; ARD, \u20134.4 pp [95% CI, \u20139.1 to 0.4 pp]) but received naltrexone at similar rates. Patients with Medicaid (AOR, 1.39 [95% CI, 1.14-1.69]; ARD, 3.5 pp [95% CI, 0.9-6.1 pp]) or Medicare Advantage (AOR, 1.40 [95% CI, 1.05-1.86]; ARD, 3.6 pp [95% CI, \u20130.6 to 7.7 pp]) were more likely to receive buprenorphine compared with those with commercial insurance. Buprenorphine access improved incrementally from 2017 to 2022, reflecting recent clinical and policy changes; however, disparities persisted.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of more than 176\u202f000 opioid-related index health care events, race and ethnicity\u2013based and insurance-based disparities in access to MOUD persisted despite efforts to expand treatment availability. These findings underscore the need for targeted interventions, including culturally tailored care, expanded access points, and policy reforms to address structural barriers and reduce inequities contributing to the overdose crisis.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.18493","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T11:31:05Z","timestamp":1750937465000},"page":"e2518493","source":"Crossref","is-referenced-by-count":22,"title":["Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder by Race and Ethnicity and Insurance Type"],"prefix":"10.1001","volume":"8","author":[{"given":"Utsha G.","family":"Khatri","sequence":"first","affiliation":[{"name":"Institute for Health Equity Research, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lopez","sequence":"additional","affiliation":[{"name":"Institute for Health Equity Research, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Ting","family":"Yen","sequence":"additional","affiliation":[{"name":"Institute for Health Equity Research, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia J.","family":"Ling","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne D.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Institute for Health Equity Research, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Ming","family":"Ngai","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Wayne State University, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"issue":"4","key":"zoi250578r2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/jamapsychiatry.2022.0004","article-title":"Evaluation of increases in drug overdose mortality rates in the US by race and ethnicity before and during the COVID-19 pandemic.","volume":"79","author":"Friedman","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"zoi250578r3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108551","article-title":"Experiences of racial discrimination in the medical setting and associations with medical mistrust and expectations of care among black patients seeking addiction treatment.","volume":"133","author":"Hall","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"9","key":"zoi250578r5","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis.","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"zoi250578r6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/ADM.0000000000001104","article-title":"Improving research on racial disparities in access to medications to treat opioid use disorders.","volume":"17","author":"Mark","year":"2023","journal-title":"J Addict Med"},{"issue":"3","key":"zoi250578r7","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.sapharm.2023.12.001","article-title":"Is there a disparity in medications for opioid use disorder based on race\/ethnicity and gender? a systematic review and meta-analysis.","volume":"20","author":"Nedjat","year":"2024","journal-title":"Res Social Adm Pharm"},{"issue":"5","key":"zoi250578r8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.5852","article-title":"Incidence of treatment for opioid use disorder following nonfatal overdose in commercially insured patients.","volume":"3","author":"Kilaru","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"19","key":"zoi250578r9","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMsa2212412","article-title":"Racial inequality in receipt of medications for opioid use disorder.","volume":"388","author":"Barnett","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi250578r10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.amepre.2022.05.006","article-title":"Racial\u2013ethnic disparities of buprenorphine and vivitrol receipt in Medicaid.","volume":"63","author":"Dunphy","year":"2022","journal-title":"Am J Prev Med"},{"key":"zoi250578r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102905","article-title":"Continuing increased access to buprenorphine in the United States via telemedicine after COVID-19.","volume":"93","author":"Davis","year":"2021","journal-title":"Int J Drug Policy"},{"key":"zoi250578r13","doi-asserted-by":"publisher","first-page":"648","DOI":"10.21105\/joss.00648","article-title":"Comorbidity: an R package for computing comorbidity scores.","volume":"3","author":"Gasparini","year":"2018","journal-title":"J Open Source Softw"},{"issue":"10","key":"zoi250578r14","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1377\/hlthaff.2023.00205","article-title":"Racial and ethnic disparities in buprenorphine receipt among Medicare beneficiaries, 2015-19.","volume":"42","author":"Miles","year":"2023","journal-title":"Health Aff (Millwood)"},{"issue":"2","key":"zoi250578r15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1001\/jama.2021.7374","article-title":"Use of medications for treatment of opioid use disorder among US Medicaid enrollees in 11 states, 2014-2018.","volume":"326","author":"Donohue","year":"2021","journal-title":"JAMA"},{"issue":"20","key":"zoi250578r16","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1001\/jama.2020.4104","article-title":"Diagnosis and treatment of opioid use disorder in 2020.","volume":"323","author":"Wakeman","year":"2020","journal-title":"JAMA"},{"issue":"10118","key":"zoi250578r17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"zoi250578r18","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1111\/add.16630","article-title":"Comparative effectiveness of extended-release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients.","volume":"119","author":"Ross","year":"2024","journal-title":"Addiction"},{"key":"zoi250578r19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.drugalcdep.2016.03.028","article-title":"Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City.","volume":"164","author":"Hansen","year":"2016","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"zoi250578r20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.3711","article-title":"Association of racial\/ethnic segregation with treatment capacity for opioid use disorder in counties in the United States.","volume":"3","author":"Goedel","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi250578r21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s11469-012-9402-5","article-title":"Drug addiction stigma in the context of methadone maintenance therapy: an investigation into understudied sources of stigma.","volume":"11","author":"Earnshaw","year":"2013","journal-title":"Int J Ment Health Addict"},{"key":"zoi250578r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ssmqr.2023.100298","article-title":"\u201cA lack of empathy:\u201d a qualitative study of Black people seeking treatment for opioid use disorder.","volume":"4","author":"Khatri","year":"2023","journal-title":"SSM Qual Res Health"},{"key":"zoi250578r23","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1370\/afm.2920","article-title":"Impact of stigma on clinician training for opioid use disorder care: a qualitative study in a primary care learning collaborative.","volume":"21","author":"Klusaritz","year":"2023","journal-title":"Ann Fam Med"},{"issue":"2","key":"zoi250578r24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.46971","article-title":"Effect of exposure to visual campaigns and narrative vignettes on addiction stigma among health care professionals: a randomized clinical trial.","volume":"5","author":"Kennedy-Hendricks","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi250578r25","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s40429-023-00489-0","article-title":"\u201cCulturally responsive\u201d substance use treatment: contemporary definitions and approaches for minoritized racial\/ethnic groups.","volume":"10","author":"Banks","year":"2023","journal-title":"Curr Addict Rep"},{"key":"zoi250578r26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.drugalcdep.2019.03.009","article-title":"Effect of lowering initiation thresholds in a primary care\u2013based buprenorphine treatment program.","volume":"200","author":"Payne","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"zoi250578r27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2019.05.002","article-title":"Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: addressing a critical care gap.","volume":"103","author":"Krawczyk","year":"2019","journal-title":"J Subst Abuse Treat"},{"key":"zoi250578r28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jhealeco.2018.06.004","article-title":"The role of health insurance on treatment for opioid use disorders: evidence from the Affordable Care Act Medicaid expansion.","volume":"60","author":"Meinhofer","year":"2018","journal-title":"J Health Econ"},{"issue":"5","key":"zoi250578r29","doi-asserted-by":"publisher","first-page":"642","DOI":"10.2105\/AJPH.2018.304338","article-title":"Impact of Medicaid expansion on access to opioid analgesic medications and medication-assisted treatment.","volume":"108","author":"Sharp","year":"2018","journal-title":"Am J Public Health"},{"issue":"1","key":"zoi250578r30","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.19066","article-title":"Association of Medicaid expansion with opioid overdose mortality in the United States.","volume":"3","author":"Kravitz-Wirtz","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi250578r31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13722-023-00405-x","article-title":"Validating opioid use disorder diagnoses in administrative data: a commentary on existing evidence and future directions.","volume":"18","author":"Scherrer","year":"2023","journal-title":"Addict Sci Clin Pract"},{"key":"zoi250578r32","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2025.209630","article-title":"What are the risk factors of non-fatal overdose among persons who use opioids? A systematic review and meta-analysis.","volume":"171","author":"Dunne","year":"2025","journal-title":"J Subst Use Addict Treat"},{"key":"zoi250578r4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1108\/S1057-6290(2012)0000014008","volume-title":"Critical Perspectives on Addiction","author":"Hansen","year":"2012"},{"key":"zoi250578r1","doi-asserted-by":"crossref","unstructured":"Spencer? MR, Garnett? MF, Mini\u00f1o? AM. Drug overdose deaths in the United States, 2002-2022. NCHS Data Briefs. 2024. Accessed September 4, 2024. https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db491.htm","DOI":"10.15620\/cdc:135849"},{"key":"zoi250578r12","unstructured":"Ali? MM, Creedon? T, Jacobus-Kantor? L, . Early changes in waivered clinicians and utilization of buprenorphine for opioid use disorder after implementation of the 2021 HHS buprenorphine practice guidelines. US Department of Health and Human Services. December 2, 2022. Accessed August 14, 2024. https:\/\/aspe.hhs.gov\/reports\/early-changes-after-2021-hhs-buprenorphine-practice-guidelines"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2835691\/khatri_2025_oi_250578_1752689393.57084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T15:00:12Z","timestamp":1753369212000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2835691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.18493","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]}}}